TY  - CONF
AU  - Szabados, B. E.
AU  - Rodriguez-Vida, A.
AU  - Duran, I.
AU  - Crabb, S. J.
AU  - van-der-Heijden, M. S.
AU  - Pous, A. Font
AU  - Gravis, G.
AU  - Herranz, U. Anido
AU  - Protheroe, A.
AU  - Ravaud, A.
AU  - Maillet, D.
AU  - Mendez, M. J.
AU  - Suarez, C.
AU  - Linch, M.
AU  - Prendergast, A.
AU  - Tyson, C.
AU  - Mousa, K.
AU  - Castellano, D.
AU  - Powles, T. B.
PY  - 2020
DO  - 10.1016/j.annonc.2020.10.211
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/25477
T2  - Annals of oncology
AB  - Background. ABACUS is a phase II single-arm study that evaluated the safety and efficacy of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) awaiting radical cystectomy (RC).Methods. This single arm, phase II study...
LA  - en
PB  - Elsevier
KW  - Cisplatin
KW  - atezolizumab
KW  - Urinary Bladder Neoplasms
KW  - Muscles
KW  - Humans
KW  - Cystectomy
KW  - Neoadjuvant Therapy
TI  - A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
TY  - conference output
VL  - 31
ER  -